Mirum Pharmaceuticals (MIRM) Gross Margin (2021 - 2026)

Mirum Pharmaceuticals' Gross Margin history runs 6 years deep, the most recent figure standing at 81.98% for Q1 2026.

• In Q1 2026, Gross Margin rose 261.0% year-over-year to 81.98%; the TTM figure through Mar 2026 stood at 81.39% (up 428.0% YoY), while the FY2025 annual figure was 80.77%, up 501.0% from the prior year.
• Gross Margin for Q1 2026 stood at 81.98%, up from 81.02% in the prior quarter.
• The five-year high for Gross Margin was 85.56% in Q2 2022, with the low at 64.03% in Q4 2023.
• The 5-year median for Gross Margin is 81.02% (2025), against an average of 79.46%.
• The sharpest annual moves came in 2022 and 2023: Gross Margin soared 4454 bps in 2022, then sank 1987 bps in 2023.
• Mirum Pharmaceuticals' Gross Margin stood at 83.9% in 2022, then slipped by 24 bps to 64.03% in 2023, then rose by 20 bps to 77.09% in 2024, then grew by 5 bps to 81.02% in 2025, then advanced by 1 bps to 81.98% in 2026.
• Business Quant data shows MIRM's Gross Margin at 81.98% in Q1 2026, 81.02% in Q4 2025, and 80.8% in Q3 2025.